News and Trends 19 Oct 2022 HealthTech Innovation Days brings European healthtech ecosystem together The 4th edition of HealthTech Innovation Days (HTID), organized by HealthTech For Care, took place recently in Paris, France. The two-day event had the objective of finding financing and encouraging new industrial partnerships to accelerate the development and market access of new products and treatments for all patients. Around 1,600 formal and informal face-to-face and […] October 19, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Oct 2022 Aqemia raises €30M for AI-enabled drug discovery pipeline Aqemia has raised €30 million ($29.5 million) in a series A funding round to scale up drug discovery, through a first-in-class technological platform combining quantum-inspired physics and machine learning. The funding was led by Eurazeo and Bpifrance through its Large Venture fund, with the participation of previous investor Elaia. In three years, Aqemia has grown […] October 19, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Oct 2022 Report says 20% of global cancer deaths could be avoided A new study by members of the Bloomberg New Economy International Cancer Coalition says at least 1.5 million deaths from cancer could be avoided each year. This is 20% of the annual global deaths resulting from cancer. The study says this could happen if international regulations around patient trials were more standardized and people placed […] October 19, 2022 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Oct 2022 Domain Therapeutics to start clinical trials of solid tumor treatment Domain Therapeutics says its immuno-oncology candidate has been cleared in Belgium and France, leading to a phase I clinical trial. It has cleared its clinical trial applications with the ANSM (Agence Nationale de Sécurité du Médicament et des produits de santé) in France and the AFMPS (Agence Fédérale des Médicaments et des Produits de Santé) […] October 19, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Oct 2022 Nucleome Therapeutics raises £37.5M to deliver precision medicines U.K. biotech company Nucleome Therapeutics Limited has closed an oversubscribed £37.5 million ($42.4 million) series A financing round. The funds will be used to advance the company’s autoimmune disease programs, fuel expansion of its dark genome atlas and further develop its pioneering platform. The financing was led by new investor M Ventures, the strategic, corporate […] October 19, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 Oct 2022 Empyrean Neuroscience launches with $22M to target CNS disorders Empyrean Neuroscience, Inc. has launched with $22 million in series A financing and a genetic engineering platform to advance a pipeline of neuroactive compounds targeting disorders of the central nervous system (CNS). The company, based in New York City and Cambridge, U.K., is founded on a proprietary platform designed to genetically engineer small molecule therapeutics […] October 18, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 Oct 2022 EditForce creates U-to-C RNA-editing technology EditForce, Inc., headquartered in Fukuoka, Japan, has created the world’s first RNA-editing technology that enables RNA-editing bases to be changed from U (uracil) to C (cytosine). The RNA editing company also demonstrated that technology works in human cells in a joint study with Takahiro Nakamura, Faculty of Agriculture, Kyushu University. The researchers said the study […] October 18, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 Oct 2022 Emergex develops vaccine for smallpox and monkeypox Emergex Vaccines Holding Limited has formulated and confirmed the synthesis and assembly of a CD8+ T cell adaptive vaccine for smallpox and monkeypox, made up predominantly of early “eclipse phase” antigens. The monkeypox virus is part of the same family of double-stranded DNA viruses (Poxviridae) as variola virus, the virus that causes smallpox; they share […] October 18, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Oct 2022 Gene activity could help identify risk of kidney cancer spreading Among patients with kidney cancer, the activity of four specific genes in the cancer cells seems to be able to predict the risk of the tumor spreading and the patient’s chances of survival. This is shown by researchers from Karolinska Institutet (KI) in Sweden in a preclinical study published in Nature Communications. “This could potentially […] October 17, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Oct 2022 Ophthalmology biopharma company Oculis combines with EBAC Oculis, SA, a global biopharmaceutical company developing treatments to save sight and improve eye care and European Biotech Acquisition Corp (EBAC), a special purpose acquisition company (SPAC), have entered into a definitive business combination agreement. Upon closing of the transaction, the company will be named Oculis Holding SA and will work to accelerate the development […] October 17, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Oct 2022 Amgen joining Evotec and TIAP to boost Canadian life science companies Evotec SE and Toronto Innovation Acceleration Partners (TIAP) have expanded LAB150, their translational BRIDGE partnership, to include Amgen as a strategic partner. The expansion goes along with a combined investment of $14 million to expedite LAB150 programs towards the formation of new companies. LAB150 was created by Evotec and TIAP in 2017 to accelerate Toronto’s […] October 17, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Oct 2022 Kira Pharmaceuticals gets approval for paroxysmal nocturnal hemoglobinuria study Kira Pharmaceuticals says the Chinese National Medical Products Administration (NMPA) has cleared the investigational new drug (IND) application for evaluation of KP104. KP104 is a first-in-class bifunctional biologic that selectively targets the alternative and terminal complement pathways, in paroxysmal nocturnal hemoglobinuria (PNH). This approval enables Phase 2 study of the efficacy, safety, tolerability, pharmacokinetics (PK), […] October 17, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email